An increasing number of biologically targeted therapies are improving MCL treatment options in both first-line and relapsed conditions, namely the proteasome inhibitor bortezomib (Velcade®), the mechanistic target of rapamycin (mTOR) inhibitor temsirolimus (Torisel®), lenalidomide and ibrutinib, the four drugs currently licensed for MCL [15]. Here, MTOR is linked to mantle cell lymphoma.